SEC Form 4 · accession 0001179110-18-004702
Editas Medicine, Inc. · EDIT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew A. F. Hack
Officer — Chief Financial Officer
Period of report
Mar 16, 2018
Accepted (ET)
Mar 20, 2018 · 5:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001650664
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 16, 2018 | M | 6,000 | $6.48 | A | 6,000 | D | |
| Common StockF2 | Mar 16, 2018 | S | 6,000 | $39.43 | D | 0 | D | |
| Common Stock | Mar 19, 2018 | M | 6,000 | $6.48 | A | 6,000 | D | |
| Common StockF3 | Mar 19, 2018 | S | 6,000 | $37.65 | D | 0 | D | |
| Common Stock | Mar 20, 2018 | M | 5,000 | $6.48 | A | 5,000 | D | |
| Common StockF4 | Mar 20, 2018 | S | 5,000 | $37.51 | D | 0 | D | |
| Common Stock | Mar 20, 2018 | M | 1,000 | $6.48 | A | 1,000 | D | |
| Common StockF5 | Mar 20, 2018 | S | 1,000 | $38.39 | D | 0 | D | |
| Common Stock | Mar 20, 2018 | M | 22,000 | $24.60 | A | 22,000 | D | |
| Common StockF6 | Mar 20, 2018 | S | 22,000 | $37.91 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F8,F7 | $6.48 | Mar 16, 2018 | M | 6,000 | D | — | Sep 13, 2025 | Common Stock | 6,000 | 60,513 | D |
| Stock Option (right to buy)F8,F7 | $6.48 | Mar 19, 2018 | M | 6,000 | D | — | Sep 13, 2025 | Common Stock | 6,000 | 54,513 | D |
| Stock Option (right to buy)F8,F7 | $6.48 | Mar 20, 2018 | M | 6,000 | D | — | Sep 13, 2025 | Common Stock | 6,000 | 48,513 | D |
| Stock Option (right to buy)F9 | $24.60 | Mar 20, 2018 | M | 22,000 | D | — | Feb 28, 2027 | Common Stock | 22,000 | 70,500 | D |
Explanation of responses
- F1The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $39.02 to $40. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $37.29 to $38.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $37.13 to $38.11. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $38.23 to $38.59. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $37.86 to $38.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019.
- F8This amount includes an additional 2,851 option shares relating to the portion of this award constituting an Incentive Stock Option that the Reporting Person inadvertently omitted in that Form 4 filed by the Reporting Person with the SEC on February 16, 2018.
- F9This option was granted on March 1, 2017 and is scheduled to vest over four years in equal monthly installments beginning on March 1, 2017 through March 1, 2021.